Published in J Exp Med on February 01, 1979
Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A (1995) 4.33
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Soluble group- and type-specific antigens from type III group B Streptococcus. Infect Immun (1980) 1.98
Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infect Immun (1992) 1.56
Group B, type III streptococcal cell wall: composition and structural aspects revealed through endo-N-acetylmuramidase-catalyzed hydrolysis. Infect Immun (1982) 1.52
Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest (1982) 1.47
Properties of a hemolysin produced by group B streptococci. Infect Immun (1980) 1.46
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun (1981) 1.22
Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies. J Exp Med (1983) 1.21
Extracellular antigens of serotype III group B streptococci. Infect Immun (1980) 1.16
Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest (1983) 1.15
Use of monoclonal antibodies in an enzyme immunoassay for rapid identification of group B Streptococcus types II and III. J Clin Microbiol (1980) 1.14
Structure and serology of the native polysaccharide antigen of type Ia group B streptococcus. Proc Natl Acad Sci U S A (1980) 1.12
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun (2002) 1.08
Isolation and characterization of type III group B streptococcal mutants defective in biosynthesis of the type-specific antigen. Infect Immun (1983) 1.08
Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect Immun (1998) 1.03
Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice. Infect Immun (2006) 1.01
Murine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparations. Infect Immun (1981) 1.01
Interaction of neonatal phagocytes with group B streptococcus: recognition and response. Infect Immun (2006) 0.99
Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun (2002) 0.99
Purification and partial characterization of neuraminidase from type III group B streptococci. J Bacteriol (1980) 0.92
Isolation, chemical composition, and molecular size of extracellular type II and type Ia polysaccharides of group B streptococci. Infect Immun (1983) 0.88
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc Natl Acad Sci U S A (2008) 0.84
Enzyme-linked immunosorbent assay for measurement of antibody to type III group B streptococci. J Clin Microbiol (1982) 0.83
Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci. Infect Immun (1984) 0.83
Immunochemical cross-reactions between type III group B Streptococcus and type 14 Streptococcus pneumoniae. Infect Immun (1979) 0.80
The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope. Glycoconj J (2011) 0.79
Structurally identical capsular polysaccharide expressed by intact group B streptococcus versus Streptococcus pneumoniae elicits distinct murine polysaccharide-specific IgG responses in vivo. J Immunol (2012) 0.78
Measurement of human antibodies to type III group B Streptococcus. Infect Immun (1999) 0.76
In vitro lymphocyte proliferation in response to type III group B streptococci. J Clin Microbiol (1982) 0.75
Pathogenesis of neonatal group B streptococcal infections. Yale J Biol Med (1983) 0.75
Type-specific antigens of group B type Ic streptococci. Infect Immun (1971) 6.84
A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B). J Exp Med (1934) 4.56
Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) (1966) 4.55
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest (1972) 3.13
Immunochemistry of purified polysaccharide type antigens of group B streptococcal types Ia, Ib, and Ic. Infect Immun (1975) 2.83
TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES. J Exp Med (1938) 2.62
Immune response after splenectomy. Lancet (1978) 2.31
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
The isolation and some physiochemical and biologic properties of the type 3 antigen of group B streptococci. J Immunol (1972) 2.04
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med (1978) 1.86
Structural studies on the specific type-14 pneumococcal polysaccharide. Carbohydr Res (1977) 1.80
Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci. J Clin Microbiol (1978) 1.18
Antibody response to capsular polysaccharide vaccine of Streptococcus pneumoniae in patients with nephrotic syndrome. J Infect Dis (1978) 0.93
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Selective broth medium for isolation of group B streptococci. Appl Microbiol (1973) 4.42
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med (1980) 3.95
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians (1976) 3.49
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. J Infect Dis (1980) 3.29
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis (1983) 3.23
The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis (1976) 3.20
Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med (1988) 3.14
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol (1981) 3.04
Active oxygen in plant pathogenesis. Annu Rev Phytopathol (1995) 3.02
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med (1977) 2.95
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Molecular cloning of a Pseudomonas syringae pv. syringae gene cluster that enables Pseudomonas fluorescens to elicit the hypersensitive response in tobacco plants. J Bacteriol (1988) 2.84
Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature (2001) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods (1980) 2.65
Virulence of three distinct Cryptosporidium parvum isolates for healthy adults. J Infect Dis (1999) 2.65
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA (1984) 2.63
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem (1975) 2.51
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
Involvement of plasma membrane calcium influx in bacterial induction of the k/h and hypersensitive responses in tobacco. Plant Physiol (1990) 2.46
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Neonatal sepsis caused by a new group B streptococcal serotype. J Pediatr (1993) 2.45
Chemical and biological characterization of the lipopolysaccharide of Bacteroides fragilis subspecies fragilis. J Infect Dis (1976) 2.45
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. J Infect Dis (1975) 2.39
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Purification of a major membrane protein of Toxoplasma gondii by immunoabsorption with a monoclonal antibody. J Immunol (1983) 2.38
A half century of neonatal sepsis at Yale: 1928 to 1978. Am J Dis Child (1981) 2.36
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A (1996) 2.34
Immune response after splenectomy. Lancet (1978) 2.31
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
In whose best interest? Breaching the academic-industrial wall. N Engl J Med (2000) 2.28
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun (1991) 2.06
A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J (1990) 2.05
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 2.02
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem (1992) 2.00
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother (1998) 2.00
Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.99
Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (1992) 1.98
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. J Clin Microbiol (1989) 1.87
Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med (1978) 1.86
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83
Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem (1980) 1.83
Neonatal mouse model of group B streptococcal infection. J Infect Dis (1992) 1.82
Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1. Biochemistry (1980) 1.80
The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J Immunol (1976) 1.80
Mouse protection test for group B Streptococcus type III. J Infect Dis (1979) 1.80